PUBLISHER: DelveInsight | PRODUCT CODE: 1048419
PUBLISHER: DelveInsight | PRODUCT CODE: 1048419
DelveInsight's, "MAP kinase kinase 1 inhibitors - Pipeline Insight, 2022" report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in MAP kinase kinase 1 inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
MAP kinase kinase 1 inhibitors Understanding
MAP kinase kinase 1 inhibitors: Overview
MAPK kinases 1 and 2 (commonly known as MEK1-2) represent such proteins as they lie downstream of important drug targets for oncology, such as EGFR, RAS and RAF. MEK inhibitors hold promise for use as combination therapies for highly prevalent, genetically defined cancers owing to the critical role that the MAPK pathway plays in the growth and proliferation of many cancer types (including lung cancer, melanoma, pancreatic cancer, colorectal cancer, endometrial cancer, and ovarian cancer).
MAP kinase kinase 1 inhibitors Emerging Drugs Chapters
This segment of the MAP kinase kinase 1 inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
MAP kinase kinase 1 inhibitors Emerging Drugs
Selumetinib is a MEK 1/2 inhibitor used in pediatric patients to treat neurofibromatosis type 1 (NF1) accompanied by symptomatic, inoperable plexiform neurofibromas (PN). Selumetinib is a non-ATP-competitive mitogen-activated protein kinase kinase 1 and 2 (MEK1 and MEK2) inhibitor.6 By selectively targeting MEK1 and MEK2, selumetinib is able to inhibit oncogenic downstream effects of the Raf-MEK-ERK signaling pathway, which is often overactive in certain types of cancer.
Mirdametinib is an oral, allosteric, small molecule MEK inhibitor in development as a monotherapy treatment for neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN) and low-grade glioma (LGG), and as a combination therapy for the treatment of several subsets of biomarker-defined metastatic solid tumors. A Phase 2 investigator-initiated trial of mirdametinib in adolescents and adults with NF1-PN showed encouraging efficacy along with a generally well-tolerated safety profile. The U.S. Food and Drug Administration (FDA) and the European Commission granted Orphan Drug designation for mirdametinib for the treatment of NF1, and the FDA granted Fast Track designation for the treatment of patients ≥ 2 years of age with NF1-PN that are progressing or causing significant morbidity.
Further product details are provided in the report……..
MAP kinase kinase 1 inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different MAP kinase kinase 1 inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 6+ key companies which are developing the MAP kinase kinase 1 inhibitors. The companies which have their MAP kinase kinase 1 inhibitors drug candidates in the most advanced stage, i.e. Phase II include, SpringWorks Therapeutics .
DelveInsight's report covers around 6+ products under different phases of clinical development like
MAP kinase kinase 1 inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
MAP kinase kinase 1 inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses MAP kinase kinase 1 inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging MAP kinase kinase 1 inhibitors drugs.
Key Questions
Current Scenario and Emerging Therapies:
Key Players
Key Products
Introduction
Executive Summary
MAP kinase kinase 1 inhibitors: Overview
Pipeline Therapeutics
Therapeutic Assessment
MAP kinase kinase 1 inhibitors - DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
Selumetinib: AstraZeneca
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Mirdametinib: SpringWorks Therapeutics
Drug profiles in the detailed report…..
Early Stage Products (Phase I and I/II)
CS 3006: CStone Pharmaceuticals
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
REC 4881: Recursion Pharmaceuticals
Drug profiles in the detailed report…..
Inactive Products
MAP kinase kinase 1 inhibitors Key Companies
MAP kinase kinase 1 inhibitors Key Products
MAP kinase kinase 1 inhibitors- Unmet Needs
MAP kinase kinase 1 inhibitors- Market Drivers and Barriers
MAP kinase kinase 1 inhibitors- Future Perspectives and Conclusion
MAP kinase kinase 1 inhibitors Analyst Views
MAP kinase kinase 1 inhibitors Key Companies
Appendix